IPF-028

Idiopathic Pulmonary Fibrosis (IPF)

Madrid 68 years old male Spain Total Cost: 184

Patient Condition

The patient sought medical treatment for progressive shortness of breath and dry cough for 1.5 years and had a history of smoking (20 pack-years). HRCT showed honeycomb lungs and grid shadows in both lungs. Lung function: FVC 54% predicted, DLCO 38% predicted. 6MWD 290m, mMRC score 3. IPF was diagnosed (GAP score 5, stage II).

Treatment Timeline

PhaseDetailsDate
diagnostic assessment
treatment initiation
Standardized treatment (months 1-12)
Maintenance treatment (Months 13-24)

Treatment Outcome

beforeFVC accounted for 54% of predicted value, DLCO accounted for 38% of predicted value, 6MWD 290m, mMRC score 3
afterAfter 24 months of treatment, FVC accounted for 49% of the predicted value (annual decline rate of approximately 2.5%), DLCO accounted for 33% of the predicted value, 6MWD was 315m, and mMRC score dropped to level 2
highlightAfter 24 months of Pirfenidone combined with pulmonary rehabilitation treatment, the decline of FVC was delayed, exercise tolerance was improved by 25 meters, and dyspnea symptoms were alleviated.